DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Taiwan
  • /
  • Healthcare
Author Program NEWCreate Narrative
6598 logo

Applied BioCode Corporation Stock Price

TWSE:6598 Community·NT$2.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

6598 Share Price Performance

NT$28.15
8.45 (42.89%)
​
NT$28.15
8.45 (42.89%)
​
Price NT$28.15
Wed, 2 Sep 26
Share Pricen/a

6598 Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with very low risk.

2 Risks
0 Rewards
View Full Analysis

Applied BioCode Corporation Key Details

NT$666.5m

Revenue

NT$251.5m

Cost of Revenue

NT$415.0m

Gross Profit

NT$463.9m

Other Expenses

-NT$48.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.48
62.27%
-7.33%
0%
View Full Analysis

About 6598

Founded
2016
Employees
n/a
CEO
Winston Z. Ho
WebsiteView website
www.apbiocode.com

Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products. In addition, it provides BioCode Fungal Panel, a multiplexed deoxyribonucleic acid (DNA) amplification test; and BioCode STI + Resistance Panel (RUO), a multiplex nucleic acid amplification test. Further, the company offers barcoded magnetic bead accessories. Applied BioCode Corporation was founded in 2016 and is based in Grand Cayman, the Cayman Islands.

Recent 6598 News & Updates

Recent updates

No updates

Applied BioCode Corporation Competitors

7799 logo

Heron Neutron Medical

Symbol: TWSE:7799
Market cap: NT$58.5b
6491 logo

Pegavision

Symbol: TWSE:6491
Market cap: NT$30.5b
7686 logo

A-Top Health Biotech

Symbol: TPEX:7686
Market cap: NT$25.3b
6782 logo

Visco Vision

Symbol: TWSE:6782
Market cap: NT$15.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide